The recent surge in investments into niche pharmaceutical companies, particularly those focusing on experimental therapies and complex drug development programs, has fueled what some are calling "High Roller Pharma." While the promise for game-changing treatments and impressive returns is clear, the connected risks are also notable. Many of thes… Read More